Wockhardt receives QIDP status from US FDA

WCK 5222 is a new class of antibiotic for gram negative terrain for complicated urinary tract infections and HABP/ VABP

Wockhardt announced that US Food and Drug Administration (US FDA) has granted WCK 5222, a product from their breakthrough new drug discovery programme in anti infectives, Qualified Infectious Disease Product (QIDP) status. This is the fourth product from Wockhardt to receive this coveted status.

Dr Habil Khorakiwala, Chairman, Wockhardt said, “We are pleased that WCK 5222 has received the coveted QIDP status, fourth for the company in quick succession. WCK 5222 is a new class of antibiotic for gram negative terrain for complicated urinary tract infections and Hospital Acquired Bacterial Pneumonia (HABP)/ VABP. We believe that when WCK 5222 is approved will save many lives world.”